PA21 Phase II Clinical Study in Hemodialysis Patients With Hyperphosphatemia
Last updated on July 2021Recruitment
- Recruitment Status
- Completed
- Estimated Enrollment
- 150
Summary
- Conditions
- Chronic Kidney Disease Requiring Hemodialysis
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: DoublePrimary Purpose: Treatment
Participation Requirements
- Age
- Between 20 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT01521494
- Collaborators
- Not Provided
- Investigators
- Study Director: Tatsuro Takei Clinical Development Department, Kissei pharmaceutical Co., Ltd.
Get Well Soon